Latest News > Firm News

PitchBook Names Great Point Partners Top Investor in Pharma & Biotech Infrastructure Since 2010


GREENWICH, CT – Great Point Partners (“GPP”) today announced that PitchBook, the leading provider of data on private equity transactions, named GPP as one of the most active pharma and biotech infrastructure investors since 2010.

Note: All platform and add-on investments from 2010 – November 17, 2015
Investor Deals
Lincoln Park Capital 10
Great Point Partners 9
TPG Capital 9
Warburg Pincus 9
Ardian 8

Great Point Partners’ first fund, GPP I, has realized three highly successful pharmaceutical and biotechnology supply chain investments. These were Caprion Proteomics, an international leader in biomarker services based in Montreal, Mediatech, a manufacturer of proprietary cell culture media, and Cytovance Biologics, the fastest growing contract manufacturer of protein and anti-body drugs in the United States. Equity investment appreciation in these companies ranged from approximately 3.4-fold to 7.4-fold.

GPP sourced two tuck-in acquisitions for Caprion Proteomics to accelerate its growth and solidify its dominant market position. As noted previously by others, GPP sources more tuck-in acquisitions per portfolio company than any other health care private equity firm.

To date GPP II, Great Point’s second growth buy-out fund, has made two pharmaceutical and biotech supply chain investments in Corrona, a leader in patient registries for post approval drug surveillance, and Softbox, a leader in temperature controlled packaging for biologics, vaccines, and active pharmaceutical ingredients. Both of these companies have been growing revenues over 20% per year since GPP’s investment.

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $900 million of equity capital under management and 26 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP II, which has closed on $215 million. Great Point manages capital in private (GPP I, $156 million, and GPP II) and public (BMVF, approximately $400 million) equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical infrastructure, devices and diagnostics, health care services, outsourcing, and information technology. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. Reach Great Point at 203-971-3300 or